Press Releases

WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

ST. LOUIS, Dec. 3, 2018 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform. The data from this study, which was led by researchers from the Washington University in St. Louis, demonstrated efficacy in preclinical mouse models and was presented in an …

WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting Read More »

WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis

ST. LOUIS, Nov. 13, 2018 /PRNewswire/ —  WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington University in St. Louis for intellectual property and technology related to CAR-T therapies. The agreement gives WUGEN exclusive rights to technology from the laboratory of noted bone marrow …

WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis Read More »

WUGEN Announces Presentations at American Society of Hematology Annual Meeting

ST. LOUIS, Nov. 1, 2018  /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an oral and poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held Dec. 1 – 4 in San Diego. The presentations …

WUGEN Announces Presentations at American Society of Hematology Annual Meeting Read More »

Scroll to Top